Early and Accurate Diagnosis of Melanoma is Critical for Long-Term Survival.1

What is myPath® Melanoma?

Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.

The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30

90% - 94%

Sensitivity

91% - 96%

Specificity

Testing Process

Submission of Lesion For Testing

A dermatopathologist sends a tissue block or unstained slides with a completed myPath Melanoma Test Request Form to Myriad.

myPath Melanoma Testing

(5-7 Days)

myPath Melanoma testing is completed in approximately 5-7 days and provides a score as well as a classification of likely benign, likely malignant, or indeterminate.

Test Score Reported via ResultsNOW™

Test results are reported to the ordering physician via Myriad’s ResultsNOW™ online portal.

Physician's Diagnosis

The physician reviews and interprets the myPath Melanoma results within the context of other clinical and histopathological information to render a final diagnosis.

How the myPath Melanoma Test Works

The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.

Covered by Medicare

9 out of 10 patients pay $0

The estimated average out-of-pocket cost

after insurance and financial assistance

Subscribe To Our Email Updates

“Melanocytic lesions continue to pose significant interpretive problems to histopathologists.”

Lorenzo Cerroni, et al

Myriad Corporate Headquarters

(800) 231-4442

320 Wakara Way

Salt Lake City, UT 84108

mypathCS@myriad.com

References     Contact     Notice of Privacy Practices     Terms of Use    Privacy Policy

Copyright © 2019 Myriad myPath Melanoma. All rights reserved.